Opportunity Information: Apply for RFA DK 14 008
Apply for RFA DK 14 008
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "Reagents for Glucagon and Incretin Research (R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on May 2, 2014 and posted on May 2, 2014.
- Applicants must submit their applications by Nov 24, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Reagents for Glucagon and Incretin Research (R43/R44) opportunity (Funding Opportunity Number RFA-DK-14-008) is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant announcement aimed at pushing forward practical tools that enable better research on glucagon biology, incretin signaling, and pancreatic islet function. The overall focus is not on basic discovery alone, but on developing and validating concrete research-enabling products such as assays and reagents that the wider research community can use to generate more accurate, reproducible, and biologically meaningful data in diabetes- and metabolism-related studies.
The FOA calls for small businesses to propose research and development projects in several specific tool-development areas. First, it seeks validated assays for measuring plasma glucagon that are highly sensitive and highly specific. This emphasis reflects long-standing technical challenges in accurately quantifying glucagon in blood, where closely related peptides and assay cross-reactivity can produce misleading results. Second, the announcement encourages development of reagents that can manipulate glucagon receptor activity in pancreatic islets and other tissues. In practice, this could include well-characterized agonists, antagonists, modulators, probes, or other research tools designed to precisely turn receptor signaling up or down in relevant experimental systems. Third, it supports creation of reagents that improve understanding of pancreatic alpha cell biology, particularly how alpha cells respond to glucagon and incretins. That area targets tools that help researchers examine alpha cell function, regulation, secretion dynamics, and adaptive responses, which are central to glucose homeostasis and diabetes pathophysiology. Fourth, the FOA highlights a need for reagents and assays that enable accurate expression and quantification of functional incretin receptors in endocrine and exocrine pancreatic cells as well as in relevant tissues outside the pancreas. This reflects the idea that receptor presence alone is not enough; tools should help confirm functional receptor expression, measure it reliably, and support comparisons across cell types and tissues.
Administratively, this is a discretionary grant program using the SBIR mechanisms R43/R44, which generally map to Phase I and Phase II small business research and development awards. The activity category is listed under Food and Nutrition Health, and the CFDA number is 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research), indicating it sits within the NIH portfolio supporting research on diabetes and related metabolic and organ-system diseases. The estimated total funding amount in the announcement is $2,000,000, and the opportunity explicitly states there is no cost sharing or matching requirement.
Eligibility is restricted to small businesses. Non-U.S. (foreign) organizations are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply. However, foreign components, as defined in the NIH Grants Policy Statement, may be allowed, which can matter for projects that require specific overseas collaborations or resources while still being led by an eligible U.S. small business applicant.
Key dates included a posted and creation date of May 2, 2014, with an original and current closing date of November 24, 2014, and an archive date of December 25, 2014. The sponsoring agency is NIH, and the full announcement was made available through the NIH grants website. For access or technical issues related to the electronic announcement, the contact listed is the NIH Office of Extramural Research (OER) Webmaster (FBOWebmaster@OD.NIH.GOV), which is the support point for problems opening the FOA or linking to it.
In practical terms, this funding opportunity is best understood as NIH support for small businesses to create rigorously validated measurement methods and biological reagents that remove common bottlenecks in glucagon and incretin research. The deliverables are meant to strengthen the reliability of experimental findings across the field by improving assay specificity, enabling controlled receptor manipulation, clarifying alpha cell responses, and making incretin receptor detection and functional quantitation more accurate across pancreas cell types and relevant peripheral tissues.
FAQs: Reagents for Glucagon and Incretin Research (R43/R44) - RFA-DK-14-008
What is this funding opportunity?
This is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) funding opportunity titled "Reagents for Glucagon and Incretin Research (R43/R44)," Funding Opportunity Number (FON) RFA-DK-14-008. It supports small businesses developing practical, research-enabling tools for glucagon biology, incretin signaling, and pancreatic islet function.
What is the main goal of the FOA?
The main goal is to advance concrete products that enable better research, with an emphasis on developing and validating assays and reagents that help the broader research community generate more accurate, reproducible, and biologically meaningful data in diabetes- and metabolism-related studies.
Is the focus basic discovery research, product development, or both?
The emphasis is on developing and validating research-enabling products rather than basic discovery alone. Projects are expected to produce practical tools such as assays and reagents that can be used by the wider research community.
Which SBIR mechanisms are used in this announcement?
The announcement uses NIH SBIR mechanisms R43/R44, which generally correspond to Phase I and Phase II small business research and development awards.
Who is eligible to apply?
Eligibility is restricted to small businesses.
Are foreign (non-U.S.) organizations eligible to apply?
No. Non-U.S. (foreign) organizations are not eligible to apply.
Can a U.S. small business include a non-U.S. component in the application?
Non-U.S. components of U.S. organizations are not eligible to apply. However, foreign components, as defined in the NIH Grants Policy Statement, may be allowed, which can be relevant when specific overseas collaborations or resources are needed while the lead applicant remains an eligible U.S. small business.
What tool-development areas does the FOA specifically encourage?
The FOA highlights several specific tool-development needs: (1) validated assays for measuring plasma glucagon that are highly sensitive and highly specific; (2) reagents to manipulate glucagon receptor activity in pancreatic islets and other tissues; (3) reagents that improve understanding of pancreatic alpha cell biology, including how alpha cells respond to glucagon and incretins; and (4) reagents and assays to enable accurate expression and quantification of functional incretin receptors in endocrine and exocrine pancreatic cells and in relevant tissues outside the pancreas.
What kind of glucagon measurement assays are being sought?
The FOA calls for validated plasma glucagon assays with high sensitivity and high specificity. This is tied to known technical problems in measuring glucagon in blood, where closely related peptides and assay cross-reactivity can lead to misleading results.
Why does the FOA emphasize specificity and sensitivity for plasma glucagon assays?
Because accurately quantifying glucagon in blood has been technically challenging, especially due to cross-reactivity and interference from closely related peptides. The FOA stresses assays that reduce misleading measurements and improve reliability.
What types of reagents are envisioned for manipulating the glucagon receptor?
The FOA describes well-characterized agonists, antagonists, modulators, probes, or other research tools designed to precisely increase or decrease glucagon receptor signaling in relevant experimental systems, including pancreatic islets and other tissues.
What is meant by tools supporting pancreatic alpha cell biology?
This refers to reagents that help researchers examine alpha cell function and regulation, including secretion dynamics and adaptive responses, particularly focusing on how alpha cells respond to glucagon and incretins. These topics are central to glucose homeostasis and diabetes pathophysiology.
What does the FOA say about incretin receptors and why new tools are needed?
The FOA highlights a need for reagents and assays that can accurately detect expression and quantify functional incretin receptors in pancreatic endocrine and exocrine cells, as well as relevant tissues outside the pancreas. The emphasis on "functional" reflects the idea that receptor presence alone is not sufficient; tools should confirm functional receptor expression and measure it reliably across cell types and tissues.
Which research areas or diseases does this opportunity relate to?
It sits within the NIH portfolio supporting diabetes and related metabolic and organ-system diseases, with a focus on diabetes- and metabolism-related studies tied to glucagon biology, incretin signaling, and pancreatic islet function.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.847, "Diabetes, Digestive, and Kidney Diseases Extramural Research."
What is the activity category listed for this program?
The activity category is listed under Food and Nutrition Health.
How much total funding is estimated under this announcement?
The estimated total funding amount in the announcement is $2,000,000.
Is cost sharing or matching required?
No. The opportunity explicitly states there is no cost sharing or matching requirement.
When was the FOA posted and when did it close?
The posted and creation date is May 2, 2014. The original and current closing date is November 24, 2014.
Has this funding opportunity been archived?
Yes. The archive date is December 25, 2014.
Which agency sponsors this FOA?
The sponsoring agency is the National Institutes of Health (NIH).
Where was the full announcement made available?
The full announcement was made available through the NIH grants website.
Who should be contacted for technical issues accessing the electronic FOA?
For access or technical issues related to the electronic announcement (such as problems opening the FOA or linking to it), the listed contact is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
What kinds of deliverables does NIH appear to be seeking from awardees?
The FOA is framed around deliverables that remove common bottlenecks in glucagon and incretin research: rigorously validated measurement methods and biological reagents that improve assay specificity, enable controlled receptor manipulation, clarify alpha cell responses, and make incretin receptor detection and functional quantitation more accurate across pancreatic cell types and relevant peripheral tissues.
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: NEI Administrative Supplements to Small Business Innovative Research (SBIR) Grants for the Procurement of Expertise in the Federal Regulatory Approval Process for New Drugs and/or Devices (Admin Supp)
Previous opportunity: Reagents for Glucagon and Incretin Research (R41/R42)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 14 008
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 14 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| Diabetes Impact Award Closed Loop Technologies Clinical, Physiological and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (DP3) Apply for RFA DK 14 014 Funding Number: RFA DK 14 014 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Diabetes Impact Award Closed Loop Technologies Development and Integration of Novel Components for an Automated Artificial Pancreas System (DP3) Apply for RFA DK 14 015 Funding Number: RFA DK 14 015 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Nutrition Obesity Research Centers (NORCs) (P30) Apply for RFA DK 14 002 Funding Number: RFA DK 14 002 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Silvio O. Conte Digestive Diseases Research Core Centers (P30) Apply for RFA DK 14 012 Funding Number: RFA DK 14 012 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Increasing the Quality and Efficiency of Clinical Trials (R18) Apply for RFA FD 14 017 Funding Number: RFA FD 14 017 Agency: Food Drug Administration Category: Food and Nutrition Health Funding Amount: $7,500,000 |
| U.S. India Bilateral Collaborative Research Partnerships (CRP) on Diabetes Research (R21) Apply for RFA DK 14 006 Funding Number: RFA DK 14 006 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $275,000 |
| Polycystic Kidney Disease (PKD) Research and Translation Core Centers (P30) Apply for RFA DK 14 013 Funding Number: RFA DK 14 013 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Research Using Biosamples From Selected Type 1 Diabetes Clinical Studies (DP3) Apply for PAR 14 257 Funding Number: PAR 14 257 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $4,000,000 |
| Research Using Subjects From Selected Type 1 Diabetes Clinical Studies (Living Biobank) (DP3) Apply for PAR 14 258 Funding Number: PAR 14 258 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $7,000,000 |
| Chronic Kidney Disease Biomarkers Consortium (CKD BioCon) (U01) Apply for RFA DK 14 011 Funding Number: RFA DK 14 011 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $450,000 |
| Improving Diabetes Management in Young Children with Type 1 Diabetes (DP3) Apply for RFA DK 14 022 Funding Number: RFA DK 14 022 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Critical Path Public Private Partnerships Apply for RFA FD 14 089 Funding Number: RFA FD 14 089 Agency: Food Drug Administration Category: Food and Nutrition Health Funding Amount: $10,500,000 |
| NIDDK Mentored Research Scientist Development Award (K01) Apply for PAR 14 266 Funding Number: PAR 14 266 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition Data Coordinating Center for The Environmental Determinants of Diabetes in the Young (TEDDY) Study (UC4) Apply for RFA DK 14 505 Funding Number: RFA DK 14 505 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $20,000,000 |
| NIAID SBIR Technology Transfer Direct Phase II (SBIR TT) (R44) Apply for RFA AI 14 049 Funding Number: RFA AI 14 049 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,000,000 |
| NIDDK Cooperative Hematology Specialized Core Centers (U54) Apply for RFA DK 14 001 Funding Number: RFA DK 14 001 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,000,000 |
| Limited Competition for the Continuation of the Adult Acute Liver Failure Study Group (U01) Apply for RFA DK 14 504 Funding Number: RFA DK 14 504 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $3,500,000 |
| NIDDK Physician Scientist Diversity Mentoring Award (K05) Apply for RFA DK 14 005 Funding Number: RFA DK 14 005 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| NIDDK Central Repositories Non renewable Sample Access (X01) Apply for PAR 14 301 Funding Number: PAR 14 301 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Type 1 Diabetes TrialNet Clinical Centers (U01) Apply for RFA DK 14 016 Funding Number: RFA DK 14 016 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $450,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 14 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.